m032
Biologicalexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02062827)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- m032
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07076498 | Phase 1 | Dec 1, 2025 | Department of Defense, University of Texas at Houston |
| NCT05084430 | Phase 1/Phase 2 (Phase 2) | Dec 20, 2021 | Merck, University of Alabama, Birmingham |
| NCT02062827 | Phase 1 | Sep 1, 2014 | University of Alabama, Birmingham |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Alabama, Birmingham | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Department of Defense | Government | 1 | 0 | 1 | 2025 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1